Paul Rivard's most recent trade in TNF Pharmaceuticals Inc. was a trade of 150,000 Common stock done at an average price of $1.1 . Disclosure was reported to the exchange on Aug. 24, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
TNF Pharmaceuticals Inc. | Paul Rivard | Chief Legal Officer | Purchase of securities on an exchange or from another person at price $ 1.11 per share. | 24 Aug 2023 | 150,000 | 400,000 | - | 1.1 | 166,500 | Common stock |
TNF Pharmaceuticals Inc. | Paul Rivard | Chief Legal Officer | Purchase of securities on an exchange or from another person at price $ 1.12 per share. | 17 Aug 2023 | 25,000 | 250,000 | - | 1.1 | 28,080 | Common stock |
TNF Pharmaceuticals Inc. | Paul Rivard | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
TNF Pharmaceuticals Inc. | Paul Rivard | EVP of Operations, GC | Purchase of securities on an exchange or from another person at price $ 1.53 per share. | 08 Dec 2022 | 10,000 | 225,000 | - | 1.5 | 15,300 | Common stock |